Phase 3 Randomized Controlled Trial Of Rondecabtagene Autoleucel, An Autologous, Dual-Targeting CD19/CD20 Car T-Cell Therapy Product Candidate, Versus Investigator's Choice Of CD19 Car T-Cell Therapy In Patients With Relapsed Or Refractory Large B-Cell Lymphoma In The Second-Line Setting (PINACLE-H2H)

Disease:

Large B-cell Lymphoma, Lymphoma, B-Cell, Relapsed Non-Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Non-Hodgkin Lymphoma Refractory/ Relapsed, Diffuse Large B Cell Lymphoma (DLBCL), Diffuse Large B Cell Lymphoma Refractory, Diffuse Large B Cell Lymphoma Relapsed

Study phase:

Phase III

Physician name:

Dai Chihara

Department:

Lymphoma/Myeloma

For general questions about clinical trials:

1-877-632-6789